Charles River Laboratories International, Inc. Common Stock (CRL)
181.68
+0.00 (0.00%)
NYSE · Last Trade: May 8th, 9:38 AM EDT
Detailed Quote
| Previous Close | 181.68 |
|---|---|
| Open | - |
| Bid | 137.00 |
| Ask | 203.00 |
| Day's Range | N/A - N/A |
| 52 Week Range | 131.30 - 228.88 |
| Volume | 15,569 |
| Market Cap | 9.16B |
| PE Ratio (TTM) | -62.65 |
| EPS (TTM) | -2.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 810,273 |
Chart
About Charles River Laboratories International, Inc. Common Stock (CRL)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively. Read More
News & Press Releases
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on y...
Via StockStory · May 8, 2026
Charles River (CRL) Q1 2026 Earnings Transcript
Via The Motley Fool · May 7, 2026
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.2% year on ...
Via StockStory · May 7, 2026
Charles River Laboratories (NYSE:CRL) Beats Q1 Estimates, Reaffirms Guidancechartmill.com
Via Chartmill · May 7, 2026
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2026. For the quarter, revenue was $995.8 million, an increase of 1.2% from $984.2 million in the first quarter of 2025.
By Charles River Laboratories International, Inc. · Via Business Wire · May 7, 2026
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings this Thursday before market hours. Here’s what investors should know. C...
Via StockStory · May 5, 2026
Charles River Laboratories today announced an enhanced In Vitro Fertility (IVF) service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes—while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated project management with optional health monitoring and genetic validation to help ensure continuity across discovery, pharmacology, and translational studies. Researchers working in these therapeutic areas can request a streamlined quote and timeline starting this quarter to keep studies on track and data flowing.
By Charles River Laboratories · Via Business Wire · April 30, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...
Via StockStory · April 30, 2026
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
Via StockStory · April 24, 2026
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Via StockStory · April 17, 2026
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2026 financial results on Thursday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7th, at 8:30 a.m. ET.
By Charles River Laboratories International, Inc. · Via Business Wire · April 16, 2026
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world’s leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives.
By Charles River Laboratories International, Inc. · Via Business Wire · April 9, 2026
What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci...
Via StockStory · April 6, 2026
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Via Chartmill · April 6, 2026
Stay informed with the top movers within the S&P500 index on Monday.chartmill.com
Via Chartmill · April 6, 2026
Monday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · April 6, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via StockStory · April 2, 2026
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Via StockStory · March 27, 2026
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via StockStory · March 27, 2026
Movers and shakers in today's after-hours session for S&P500 stocks?chartmill.com
Via Chartmill · March 16, 2026
Which stocks are moving after the closing bell on Monday?chartmill.com
Via Chartmill · March 16, 2026
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Via Chartmill · March 12, 2026
These S&P500 stocks are moving in today's sessionchartmill.com
Via Chartmill · March 12, 2026
Over the past six months, Charles River Laboratories has been a great trade, beating the S&P 500 by 7.5%. Its stock price has climbed to $168.91, representin...
Via StockStory · March 12, 2026